Are Randomized Controlled Trials Necessary to Establish the Value of Implementing Pharmacogenomics in the Clinic?

被引：30

作者：

Huddart, Rachel ^{[1
]}

Sangkuhl, Katrin ^{[1
]}

Whirl-Carrillo, Michelle ^{[1
]}

Klein, Teri E. ^{[1
,2
]}

机构：

[1] Stanford Univ, Dept Biomed Data Sci, Stanford, CA 94305 USA

[2] Stanford Univ, Dept Med, Stanford, CA 94305 USA

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2019年 / 106卷 / 02期

关键词：

D O I：

10.1002/cpt.1420

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Pharmacogenomics can personalize drug prescribing to individual patients, increasing drug efficacy and reducing incidence of adverse drug reactions (ADRs). Despite a substantial evidence base and published pharmacogenomic guidelines, a lack of evidence from randomized controlled trials (RCTs) is frequently cited as a reason to delay implementation of pharmacogenomics in the clinic. We believe that this argument is misguided as RCTs are unnecessary for implementation and can obscure important pharmacogenomic factors which may affect drug response.

引用

页码：284 / 286

页数：3

共 5 条

[1] HLA Diversity in the 1000 Genomes Dataset [J].

Gourraud, Pierre-Antoine ;

Khankhanian, Pouya ;

Cereb, Nezih ;

Yang, Soo Young ;

Feolo, Michael ;

Maiers, Martin ;

Rioux, John D. ;

Hauser, Stephen ;

Oksenberg, Jorge .

PLOS ONE, 2014, 9 (07)

[2] When will clinical trials finally reflect diversity? [J].

Knepper, Todd C. ;

McLeod, Howard L. .

NATURE, 2018, 557 (7704) :157-159

[3] Pharmacogenetic tests: the need for a level playing field [J].

Pirmohamed, Munir ;

Hughes, Dyfrig A. .

NATURE REVIEWS DRUG DISCOVERY, 2013, 12 (01) :3-4

[4] Promises and challenges of pharmacogenetics: an overview of study design, methodological and statistical issues [J].

Ross, Stephanie ;

Anand, Sonia S. ;

Joseph, Philip ;

Pare, Guillaume .

JRSM CARDIOVASCULAR DISEASE, 2012, 1 (01)

[5] Pharmacogenomic substudies of randomized controlled trials: consideration of safety outcomes [J].

Sorich, Michael J. ;

Rowland, Andrew ;

Wiese, Michael D. .

THERAPEUTIC ADVANCES IN DRUG SAFETY, 2014, 5 (02) :62-66

← 1 →